Is Dishman Carbogen overvalued or undervalued?

As of 1 October 2025, the valuation grade for Dishman Carbogen has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios highlight this assessment: the PE ratio stands at 36.29, the EV to EBITDA ratio is 10.67, and the PEG ratio is notably low at 0.24, suggesting strong growth potential relative to its price. In comparison to its peers, Dishman Carbogen's valuation metrics are compelling. For instance, Sun Pharma has a PE ratio of 34.22 and an EV to EBITDA of 23.17, while Divi's Lab is marked as very expensive with a PE of 65.66 and an EV to EBITDA of 48.04. Despite a recent dip in stock performance over the past week, Dishman Carbogen has outperformed the Sensex over the past year with a return of 51.28% compared to the Sensex's decline of 3.90%. This reinforces the notion that the company is currently undervalued in the market.